These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 12012302)

  • 1. Outcome predictions for patients with metastatic prostate cancer.
    Smaletz O; Scher HI
    Semin Urol Oncol; 2002 May; 20(2):155-63. PubMed ID: 12012302
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum markers as a predictor of response duration and patient survival after hormonal therapy for metastatic carcinoma of the prostate.
    Smith JA; Lange PH; Janknegt RA; Abbou CC; deGery A
    J Urol; 1997 Apr; 157(4):1329-34. PubMed ID: 9120932
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association of body mass index with response and survival in men with metastatic prostate cancer: Southwest Oncology Group trials 8894 and 9916.
    Montgomery RB; Goldman B; Tangen CM; Hussain M; Petrylak DP; Page S; Klein EA; Crawford ED;
    J Urol; 2007 Nov; 178(5):1946-51; discussion 1951. PubMed ID: 17868721
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic factors influencing prostate cancer-specific survival in non-castrate patients with metastatic prostate cancer.
    Ost P; Decaestecker K; Lambert B; Fonteyne V; Delrue L; Lumen N; Ameye F; De Meerleer G
    Prostate; 2014 Feb; 74(3):297-305. PubMed ID: 24395565
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Radical prostatectomy and adjuvant endocrine therapy for prostate cancer with or without preoperative androgen deprivation: Five-year results.
    Homma Y; Akaza H; Okada K; Yokoyama M; Moriyama N; Usami M; Hirao Y; Tsushima T; Sakamoto A; Ohashi Y; Aso Y;
    Int J Urol; 2004 May; 11(5):295-303. PubMed ID: 15147545
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relative effectiveness and cost-effectiveness of methods of androgen suppression in the treatment of advanced prostate cancer.
    Seidenfeld J; Samson DJ; Aronson N; Albertson PC; Bayoumi AM; Bennett C; Brown A; Garber A; Gere M; Hasselblad V; Wilt T; Ziegler K
    Evid Rep Technol Assess (Summ); 1999 May; (4):i-x, 1-246, I1-36, passim. PubMed ID: 11098244
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The prognostic importance of prostate specific antigen in the monitorisation of patients undergoing maximum androgen blockade for metastatic prostate cancer.
    Kiper A; Yiğitbasi O; Imamoglu A; Tuygun C; Turan C
    Int Urol Nephrol; 2006; 38(3-4):571-6. PubMed ID: 17171425
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Outcomes and Prognostic Factors in Men Receiving Androgen Deprivation Therapy for Prostate Cancer Recurrence after Radical Prostatectomy.
    Ravi P; Karnes RJ; Rangel LJ; Pagliaro LC
    J Urol; 2018 Nov; 200(5):1075-1081. PubMed ID: 29709664
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic Factors for Survival in Noncastrate Metastatic Prostate Cancer: Validation of the Glass Model and Development of a Novel Simplified Prognostic Model.
    Gravis G; Boher JM; Fizazi K; Joly F; Priou F; Marino P; Latorzeff I; Delva R; Krakowski I; Laguerre B; Walz J; Rolland F; Théodore C; Deplanque G; Ferrero JM; Pouessel D; Mourey L; Beuzeboc P; Zanetta S; Habibian M; Berdah JF; Dauba J; Baciuchka M; Platini C; Linassier C; Labourey JL; Machiels JP; El Kouri C; Ravaud A; Suc E; Eymard JC; Hasbini A; Bousquet G; Soulie M; Oudard S
    Eur Urol; 2015 Aug; 68(2):196-204. PubMed ID: 25277272
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2006 update of an American Society of Clinical Oncology practice guideline.
    Loblaw DA; Virgo KS; Nam R; Somerfield MR; Ben-Josef E; Mendelson DS; Middleton R; Sharp SA; Smith TJ; Talcott J; Taplin M; Vogelzang NJ; Wade JL; Bennett CL; Scher HI;
    J Clin Oncol; 2007 Apr; 25(12):1596-605. PubMed ID: 17404365
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of nomograms for predicting survival in patients with castrate prostate cancer.
    Galsky M; Kelly WK
    Urology; 2003 Dec; 62 Suppl 1():119-27. PubMed ID: 14747049
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intermediate end point for prostate cancer-specific mortality following salvage hormonal therapy for prostate-specific antigen failure.
    D'Amico AV; Moul JW; Carroll PR; Cote K; Sun L; Lubeck D; Renshaw AA; Loffredo M; Chen MH
    J Natl Cancer Inst; 2004 Apr; 96(7):509-15. PubMed ID: 15069112
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Prognostic factors for PSA relapse of prostate cancer after endocrine therapy].
    Nakata S; Nakano K; Takahashi H; Shimizu K; Kawashima K
    Nihon Hinyokika Gakkai Zasshi; 2005 Nov; 96(7):685-90. PubMed ID: 16363654
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The importance of prognostic factors in the interpretation of two EORTC metastatic prostate cancer trials. European Organization for Research and Treatment of Cancer (EORTC) Genito-Urinary Tract Cancer Cooperative Group.
    Sylvester RJ; Denis L; de Voogt H
    Eur Urol; 1998; 33(2):134-43. PubMed ID: 9519354
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prostate cancer patient subsets showing improved bNED control with adjuvant androgen deprivation.
    Anderson PR; Hanlon AL; Movsas B; Hanks GE
    Int J Radiat Oncol Biol Phys; 1997 Dec; 39(5):1025-30. PubMed ID: 9392540
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Early results of radical prostatectomy and adjuvant endocrine therapy for prostate cancer with or without preoperative androgen deprivation. The Prostate Cancer Study Group.
    Homma Y; Akaza H; Okada K; Yokoyama M; Moriyama N; Usami M; Hirao Y; Tsushima T; Sakamoto A; Ohashi Y; Aso Y
    Int J Urol; 1999 May; 6(5):229-37; discussion 238-9. PubMed ID: 10375185
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combined androgen blockade.
    Crawford ED
    Eur Urol; 1996; 29 Suppl 2():54-61. PubMed ID: 8717465
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prospective evaluation of testosterone fluctuations during a transition of therapy from degarelix to leuprolide in patients on androgen deprivation therapy.
    Zuckerman JM; Eure G; Malcolm J; Currie L; Given R
    Urology; 2014 Mar; 83(3):670-4. PubMed ID: 24360065
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combined hormonal and radiation therapy for lymph node-positive prostate cancer.
    Whittington R; Malkowicz B; Barnes MM; Broderick GA; Van Arsdalen K; Dougherty MJ; Wein AJ
    Urology; 1995 Aug; 46(2):213-9. PubMed ID: 7542824
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neoadjuvant hormonal therapy prior to radical prostatectomy: evaluation of pathological downstaging and biochemical relapse.
    Kiriyama I; Ogaki K; Ohba S; Nishimura T
    J Nippon Med Sch; 2002 Oct; 69(5):422-7. PubMed ID: 12382001
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.